Search results for "Elea"

showing 10 items of 772 documents

Acute effects of different foam rolling volumes in the interset rest period on maximum repetition performance

2017

Background - Foam rolling (FR) is a ubiquitous intervention utilised for the purpose of acutely increasing the range of motion without subsequent decreases in performance. Thus, it is commonly used during the periworkout period—that is, prior to, during, or after an athlete's workout.\ud \ud Objective - This study investigated how different FR durations applied to the quadriceps during the interset rest periods affects the numbers of repetitions in the knee extension exercise.\ud \ud Methods - Twenty-five females completed four sets of knee extensions with 10 repetitions of maximum load to concentric failure on four occasions. Between each set, a 4-minute rest interval was implemented in wh…

Acute effectsmedicine.medical_specialtyB100Physical Therapy Sports Therapy and RehabilitationmassageConcentric03 medical and health sciencesself-myofascial release0302 clinical medicineRest (finance)Medicine030222 orthopedicsRepetition (rhetorical device)business.industrylcsh:RM1-950030229 sport sciencesConfidence intervalself-manual therapyRest periodlcsh:Therapeutics. PharmacologyPhysical therapyfatigueFoam rollingbusinessRange of motionResearch Paper
researchProduct

Does Preoperative Treatment with a Gonadotropin-Releasing Hormone Agonist Improve the Outcome of Endometrial Resection?

1998

Abstract Study Objective. To verify if more favorable long-term results of endometrial resection can be obtained with preoperative gonadotropin-releasing hormone (GnRH) agonist treatment. Design. Multicenter, randomized, controlled trial (Canadian Task Force classification I). Setting. Tertiary care academic department. Patients. Sixty-three premenopausal women with established menorrhagia. Intervention. Eight weeks of goserelin depot treatment before endometrial resection or immediate surgery in the early proliferative phase of the cycle. Measurements and Main Results. Variations in menstrual patterns and bleeding scores as well as overall degree of satisfaction with treatment were determi…

AdultAgonistmedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.drug_classlaw.inventionEndometriumRandomized controlled triallawGonadotropin-releasing hormone agonistPreoperative CareFollicular phaseElectrocoagulationmedicineHumansProspective StudiesMenorrhagiabusiness.industryGoserelinObstetrics and GynecologyEndoscopyMiddle AgedSurgeryExact testTreatment OutcomeDelayed-Action PreparationsUterine NeoplasmsGoserelinFemaleAmenorrheamedicine.symptombusinessAdenomyomamedicine.drugHormone
researchProduct

Cancer consequences of the Chernobyl accident in Europe outside the former USSR: A review

1996

The accident which occurred during the night of April 25-26, 1986 in reactor 4 of the Chernobyl nuclear power plant in the Ukraine released considerable amounts of radioactive substances into the environment. Outside the former USSR, the highest levels of contamination were recorded in Bulgaria, Austria, Greece and Romania, followed by other countries of Central, Southeast and Northern Europe. Studies of the health consequences of the accident have been carried out in these countries, as well as in other countries in Europe. This report presents the results of a critical review of cancer studies of the exposed population in Europe, carried out on the occasion of the 10th anniversary of the …

AdultCancer Researchmedicine.medical_specialtyNeoplasms Radiation-InducedAdolescentEnvironmental protectionNeoplasmsmedicineHumansThyroid NeoplasmsChildSocioeconomicsAccident (philosophy)AgedLeukemia Radiation-InducedHealth consequencesIncidencePublic healthInfant NewbornInfantDose-Response Relationship RadiationEnvironmental exposureMiddle Agedcancer ; thyroid ; leukaemia ; nuclear accident ; ChernobylEuropeGeographyOncologyChild PreschoolRadioactive Hazard ReleaseUkrainePower PlantsInternational Journal of Cancer
researchProduct

CORTICOTROPIN-RELEASING-FACTOR INDUCED PITUITARY-ADRENAL RESPONSE IN DEPRESSION

1984

AdultDepressive Disordermedicine.medical_specialtyCorticotropin-Releasing Hormonebusiness.industryPituitary-Adrenal SystemGeneral MedicineMiddle AgedEndocrinologyInternal medicineHumansMedicinebusinessDepression (differential diagnoses)The Lancet
researchProduct

GH responses to two consecutive bouts of neuromuscular electrical stimulation in healthy adults.

2008

BackgroundIt is well established that repeated GHRH administration or repeated voluntary exercise bouts are associated with a complete blunting of GH responsiveness when the administration of the second stimulus follows the first one after a 2-h interval.AimTo evaluate GH responses to neuromuscular electrical stimulation (NMES) in healthy adults.MethodsSix volunteers (mean age±s.d. 31.7±5.5 years) were studied before and after two consecutive bouts of NMES exercise (a series of 20 contractions at the maximum of individual tolerance, frequency: 75 Hz, pulse duration: 400 μs, on–off ratio: 6.25–20 s) administered at a 2-h interval.ResultsBaseline GH levels (mean: 0.3±0.2 ng/ml) significantly …

AdultFeedback PhysiologicalMalemedicine.medical_specialtyHydrocortisonebusiness.industryHuman Growth HormoneEndocrinology Diabetes and MetabolismArea under the curveStimulationGeneral MedicineStimulus (physiology)Growth Hormone-Releasing HormoneElectric StimulationQuadriceps MuscleEndocrinologyEndocrinologyInternal medicinemedicineHumansLactic AcidMuscle StrengthbusinessExerciseEuropean journal of endocrinology
researchProduct

Pituitary-adrenal responses to corticotropin-releasing factor in late onset 21-hydroxylase deficiency

1990

Intravenous corticotropin-releasing factor (CRF) and adrenocorticotropin hormone (ACTH) were administered in patients with adult onset 21-hydroxylase deficiency to compare their diagnostic capability as well as to investigate hypothalamic-pituitary-adrenal function in this disorder. Responses of 17-hydroxyprogesterone, which were markedly elevated compared with controls, were identical with CRF and ACTH. However, intravenous ACTH resulted in higher androstenedione levels in comparison to CRF. Adrenocorticotropin hormone also resulted in decreased cortisol responses, confirming a defect in steroidogenesis, a finding that was not evident with CRF. Plasma ACTH responses to CRF were similar in …

AdultHirsutismendocrine systemmedicine.medical_specialtyAdolescentCorticotropin-Releasing HormoneLate onsetPeptide hormoneDecreased cortisolAdrenocorticotropic HormoneInternal medicineAdrenal GlandsHydroxyprogesteronesmedicineHumansTestosteroneIn patientAndrostenedioneAdrenal Hyperplasia Congenitalbiologybusiness.industry17-alpha-HydroxyprogesteroneAndrostenedione21-HydroxylaseObstetrics and GynecologyDiagnostic testEndocrinologyReproductive MedicinePituitary GlandSteroid Hydroxylasesbiology.proteinFemalebusinesshormones hormone substitutes and hormone antagonistsHormoneFertility and Sterility
researchProduct

Ovine corticotropin-releasing factor and dexamethasone responses in hyperandrogenic women

1990

Eighteen hyperandrogenic, hirsute women received ovine corticotropin-releasing factor (CRF; 1 microgram/kg) as well as a dexamethasone (DEX) suppression test. Nine of the 18 hirsute women exhibited increased DEX sensitivity. Plasma adrenocorticotropic hormone (ACTH) responses after ovine CRF were significantly lower in the DEX-sensitive subgroup, but serum androstenedione was higher. Baseline serum androgen levels could not predict DEX responses. A significant negative correlation existed between the suppression of androgens after DEX and the increase in ACTH after ovine CRF. The suppression of androgen correlated with the ratio of the increase in androgen to the increase in ACTH after ovin…

AdultHirsutismendocrine systemmedicine.medical_specialtyAdolescentCorticotropin-Releasing Hormonemedicine.drug_classMicrogramAdrenocorticotropic hormoneDexamethasoneAdrenocorticotropic HormoneInternal medicinepolycyclic compoundsAnimalsHumansMedicineAndrostenedioneDexamethasonehirsutismSheepbusiness.industryHyperandrogenismObstetrics and GynecologyAndrogen AntagonistsAndrogenmedicine.diseasePathophysiologyEndocrinologyReproductive MedicineAndrogensFemalebusinesshormones hormone substitutes and hormone antagonistsmedicine.drugFertility and Sterility
researchProduct

Physiological Estrogen Replacement May Enhance the Effectiveness of the Gonadotropin-Releasing Hormone Agonist in the Treatment of Hirsutism

1994

GnRH agonists (GnRH-A) have been used for the treatment of hirsutism in women with ovarian hyperandrogenism. However, significant side-effects, including vasomotor symptoms and bone loss, have prevented the long term use of this therapy. In this study, we evaluated the effects of low dose (physiological) estrogen replacement on the side-effects and clinical and hormonal parameters of 22 hirsute women with ovarian hyperandrogenism when treated with a long-acting GnRH-A, Decapeptyl. Ten patients with Ferriman-Gallwey (FG) scores averaging 13.4 +/- 1.5 were randomly assigned to be treated with Decapeptyl alone (3.75 mg, im, every 28 days for 6 months), and 12 other patients with FG scores aver…

AdultHirsutismendocrine systemmedicine.medical_specialtyAdolescentmedicine.drug_classEndocrinology Diabetes and MetabolismClinical BiochemistryOvaryMedroxyprogesterone AcetateGonadotropin-releasing hormoneBiochemistryGonadotropin-Releasing HormoneEndocrinologyGonadotropin-releasing hormone agonistInternal medicinemedicineHumansMedroxyprogesterone acetateEstrogen replacementConjugated Equine EstrogensTestosteronehirsutismTriptorelin PamoateVasomotorbusiness.industryEstrogen Replacement TherapyBiochemistry (medical)HyperandrogenismObstetrics and GynecologyDrug SynergismGeneral Medicinemedicine.diseaseMenstruationmedicine.anatomical_structureEndocrinologyEstrogenGonadotropins PituitaryAndrogensDrug Therapy CombinationFemalebusinesshormones hormone substitutes and hormone antagonistsHormonemedicine.drugObstetrical & Gynecological Survey
researchProduct

Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis

2011

Objective: To analyze the impact of LH administration on cycle outcome in ovarian stimulation with GnRH antagonists. Design: Randomized, open-label, controlled trial performed in two age subgroups. Recombinant (r) FSH versus rFSH + rLH administration was compared. Setting: University-affiliated private infertility clinic. Patient(s): Up to 35 years old (n = 380) and aged 36 to 39 years (n = 340), undergoing their first or second IVF cycle. Intervention(s): Recombinant LH administration since stimulation day 1. Main Outcome Measure(s): Implantation rate, ongoing pregnancy rate. Result(s): In the young population, implantation rates were similar: 27.8% versus 28.6%, odds ratio (OR) 1.03 (95% …

AdultInfertilitymedicine.medical_specialtyPregnancy Ratemedicine.drug_classmedicine.medical_treatmentGonadotropin-releasing hormone antagonistGonadotropin-Releasing HormoneOvulation InductionPregnancymedicineGnRH antagonistHumansEmbryo ImplantationSperm Injections IntracytoplasmicGynecologyPregnancyIn vitro fertilisationbusiness.industryObstetrics and GynecologyOdds ratioLuteinizing Hormonemedicine.diseaseRecombinant ProteinsConfidence intervalPregnancy rateReproductive Medicineluteinizing hormoneDrug Therapy CombinationFemaleOvarian stimulationFollicle Stimulating HormoneLuteinizing hormonebusinessInfertility Femalein vitro fertilizationMaternal Age
researchProduct

Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans

2006

Abstract Objective The number of active pharmaceutical ingredients (API) undergoing inhibitable and saturable intestinal efflux is considerable. As a consequence, absorption and bioavailability may depend on the intestinal concentration profile of the drug and may vary as a function of dose and release rate of the drug from the dosage form. The impact of controlled versus immediate-release on the absorption of P-glycoprotein substrates is currently unknown. Thus, the main focus of the present study was a comparison of the pharmacokinetics of the P-gp model substrate talinolol following administration of immediate-release (IR) and controlled-release (CR) tablets to healthy human volunteers w…

AdultMaleActive ingredientChemistryPharmaceutical ScienceAbsorption (skin)PharmacologyCrossover studyControlled releaseDosage formBioavailabilityPropanolamineschemistry.chemical_compoundIntestinal AbsorptionSolubilityPharmacokineticsDelayed-Action PreparationsHumansFemaleATP Binding Cassette Transporter Subfamily B Member 1TabletsTalinololEuropean Journal of Pharmaceutical Sciences
researchProduct